下一代流感疫苗。
Next-Generation Influenza Vaccines.
机构信息
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
出版信息
Cold Spring Harb Perspect Med. 2021 Aug 2;11(8):a038448. doi: 10.1101/cshperspect.a038448.
Abstract
Most currently used conventional influenza vaccines are based on 1940s technology. Advances in vaccine immunogen design and delivery emerging over the last decade promise new options for improving influenza vaccines. In addition, new technologies for immune profiling provide better-defined immune correlates of protection and precise surrogate biomarkers for vaccine evaluations. Major technological advances include single-cell analysis, high-throughput antibody discovery, next-generation sequencing of antibody gene transcripts, antibody ontogeny, structure-guided immunogen design, nanoparticle display, delivery and formulation options, and better adjuvants. In this review, we provide our prospective outlook for improved influenza vaccines in the foreseeable future.
摘要
目前大多数常用的常规流感疫苗都是基于 20 世纪 40 年代的技术。过去十年中出现的疫苗免疫原设计和传递方面的进展，有望为改进流感疫苗提供新的选择。此外，用于免疫分析的新技术提供了更明确的保护免疫相关因素和疫苗评估的精确替代生物标志物。主要技术进步包括单细胞分析、高通量抗体发现、抗体基因转录本的下一代测序、抗体个体发生、基于结构的免疫原设计、纳米颗粒展示、传递和配方选择，以及更好的佐剂。在这篇综述中，我们对可预见的未来改进型流感疫苗提出了前瞻性展望。
相似文献
1
Next-Generation Influenza Vaccines.下一代流感疫苗。
Cold Spring Harb Perspect Med. 2021 Aug 2;11(8):a038448. doi: 10.1101/cshperspect.a038448.
2
Adjuvanted influenza vaccines.佐剂流感疫苗。
Hum Vaccin Immunother. 2018 Mar 4;14(3):550-564. doi: 10.1080/21645515.2017.1415684. Epub 2018 Jan 25.
3
Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.加强流感疫苗病毒的选择与研发过程：2014年4月1 - 3日于瑞士日内瓦世界卫生组织总部举行的第三次世卫组织改进流感疫苗病毒选择非正式磋商会报告
Vaccine. 2015 Aug 26;33(36):4368-82. doi: 10.1016/j.vaccine.2015.06.090. Epub 2015 Jul 3.
4
Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.免疫保护相关性分析及佐剂在提高老年人流感疫苗效果中的潜在作用。
Expert Rev Vaccines. 2013 Jul;12(7):759-66. doi: 10.1586/14760584.2013.811193.
5
Bringing influenza vaccines into the 21st century.让流感疫苗步入21世纪。
Hum Vaccin Immunother. 2014;10(3):600-4. doi: 10.4161/hv.27600. Epub 2013 Dec 30.
6
Adjuvanted influenza vaccines.佐剂流感疫苗。
Expert Rev Vaccines. 2013 Sep;12(9):1095-108. doi: 10.1586/14760584.2013.825445.
7
Influenza control in the 21st century: Optimizing protection of older adults.21世纪的流感防控：优化对老年人的保护。
Vaccine. 2009 Aug 13;27(37):5043-53. doi: 10.1016/j.vaccine.2009.06.032. Epub 2009 Jun 24.
8
Vaccines for seasonal and pandemic influenza.季节性流感和大流行性流感疫苗。
J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8. doi: 10.1086/507544.
9
Immunological assessment of influenza vaccines and immune correlates of protection.流感疫苗的免疫学评估和保护的免疫相关因素。
Expert Rev Vaccines. 2013 May;12(5):519-36. doi: 10.1586/erv.13.35.
10
[ADJUVANTED INFLUENZA VACCINES: DATA FROM DIRECT COMPARATIVE STUDIES].[佐剂流感疫苗：直接比较研究的数据]
Zh Mikrobiol Epidemiol Immunobiol. 2015 Sep-Oct(5):88-102.
引用本文的文献
1
Stabilization of H5 highly pathogenic avian influenza hemagglutinin improves vaccine-elicited neutralizing antibody responses.H5高致病性禽流感血凝素的稳定化可改善疫苗引发的中和抗体反应。
bioRxiv. 2025 Aug 2:2025.07.30.667762. doi: 10.1101/2025.07.30.667762.
2
Computationally designed stem-epitope mimetics elicit broadly reactive antibodies.通过计算设计的茎表位模拟物可引发广泛反应性抗体。
bioRxiv. 2025 Jan 22:2025.01.22.634229. doi: 10.1101/2025.01.22.634229.
3
Vaccines work… and do not cause autism.疫苗是有效的……且不会导致自闭症。
PLoS Biol. 2025 Apr 18;23(4):e3003143. doi: 10.1371/journal.pbio.3003143. eCollection 2025 Apr.
4
The applications of live attenuated influenza a virus with modified NS1 gene.具有修饰NS1基因的甲型流感病毒减毒活疫苗的应用。
Mol Ther Nucleic Acids. 2025 Feb 1;36(1):102471. doi: 10.1016/j.omtn.2025.102471. eCollection 2025 Mar 11.
5
Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA Stem Region in Human Sera Following Seasonal Vaccination.季节性疫苗接种后人体血清中针对流感HA茎区的交叉反应性Fc介导抗体反应
Vaccines (Basel). 2025 Jan 28;13(2):140. doi: 10.3390/vaccines13020140.
6
Health impact and cost-effectiveness of vaccination using potential next-generation influenza vaccines in Thailand: a modelling study.泰国使用潜在下一代流感疫苗的疫苗接种的健康影响和成本效益：建模研究。
BMJ Glob Health. 2024 Nov 18;9(11):e015837. doi: 10.1136/bmjgh-2024-015837.
7
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.评估2组流感血凝素稳定化茎部纳米颗粒疫苗的1期剂量递增试验。
NPJ Vaccines. 2024 Sep 17;9(1):171. doi: 10.1038/s41541-024-00959-0.
8
Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G.基于附着蛋白G的呼吸道合胞病毒纳米颗粒疫苗的设计与临床前评估
Vaccines (Basel). 2024 Mar 12;12(3):294. doi: 10.3390/vaccines12030294.
9
Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase.保护性人源单克隆抗体针对流感病毒神经氨酸酶底面的保守弱点部位。
Immunity. 2024 Mar 12;57(3):574-586.e7. doi: 10.1016/j.immuni.2024.02.003. Epub 2024 Mar 1.
10
Novel Influenza Vaccines: From Research and Development (R&D) Challenges to Regulatory Responses.新型流感疫苗：从研发挑战到监管应对
Vaccines (Basel). 2023 Oct 9;11(10):1573. doi: 10.3390/vaccines11101573.
本文引用的文献
1
Synthetic Virology: Building Viruses to Better Understand Them.合成病毒学：构建病毒以更好地理解它们。
Cold Spring Harb Perspect Med. 2020 Nov 2;10(11):a038703. doi: 10.1101/cshperspect.a038703.
2
Influenza Hemagglutinin Structures and Antibody Recognition.流感血凝素结构与抗体识别
Cold Spring Harb Perspect Med. 2020 Aug 3;10(8):a038778. doi: 10.1101/cshperspect.a038778.
3
Structure and Function of the Influenza Virus Transcription and Replication Machinery.流感病毒转录和复制机制的结构与功能。
Cold Spring Harb Perspect Med. 2020 Sep 1;10(9):a038398. doi: 10.1101/cshperspect.a038398.
4
Immunity to Influenza Infection in Humans.人类对流感感染的免疫力。
Cold Spring Harb Perspect Med. 2021 Mar 1;11(3):a038729. doi: 10.1101/cshperspect.a038729.
5
Neutralizing and Neuraminidase Antibodies Correlate With Protection Against Influenza During a Late Season A/H3N2 Outbreak Among Unvaccinated Military Recruits.在未接种疫苗的新兵中，针对季节性 A/H3N2 爆发的流感，中和抗体和神经氨酸酶抗体与保护作用相关。
Clin Infect Dis. 2020 Dec 15;71(12):3096-3102. doi: 10.1093/cid/ciz1198.
6
Broadly protective human antibodies that target the active site of influenza virus neuraminidase.广谱保护性人源抗体靶向流感病毒神经氨酸酶的活性位点。
Science. 2019 Oct 25;366(6464):499-504. doi: 10.1126/science.aay0678.
7
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.嵌合血凝素为基础的通用流感病毒疫苗候选物的免疫原性：一项随机、安慰剂对照、1 期临床试验的中期结果。
Lancet Infect Dis. 2020 Jan;20(1):80-91. doi: 10.1016/S1473-3099(19)30393-7. Epub 2019 Oct 17.
8
Influenza A Virus Hemagglutinin-Neuraminidase-Receptor Balance: Preserving Virus Motility.甲型流感病毒血凝素-神经氨酸酶-受体平衡：维持病毒的运动性。
Trends Microbiol. 2020 Jan;28(1):57-67. doi: 10.1016/j.tim.2019.08.010. Epub 2019 Oct 17.
9
M2e-based universal influenza vaccines: a historical overview and new approaches to development.基于 M2e 的通用流感疫苗：历史概述及新的开发方法。
J Biomed Sci. 2019 Oct 19;26(1):76. doi: 10.1186/s12929-019-0572-3.
10
The 1918 influenza pandemic: 100 years of questions answered and unanswered.1918 年流感大流行：百年未解之谜。
Sci Transl Med. 2019 Jul 24;11(502). doi: 10.1126/scitranslmed.aau5485.
Zotero 插件